NO20043842L - New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX - Google Patents

New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX

Info

Publication number
NO20043842L
NO20043842L NO20043842A NO20043842A NO20043842L NO 20043842 L NO20043842 L NO 20043842L NO 20043842 A NO20043842 A NO 20043842A NO 20043842 A NO20043842 A NO 20043842A NO 20043842 L NO20043842 L NO 20043842L
Authority
NO
Norway
Prior art keywords
preparation
processes
forms
atorvastatin hemicalcium
new
Prior art date
Application number
NO20043842A
Other languages
Norwegian (no)
Inventor
Judith Aronhime
Revital Lifshitz-Liron
Dalia Maidan-Hanoch
Limor Tessler
Nir Hasson
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20043842L publication Critical patent/NO20043842L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20043842A 2002-02-15 2004-09-14 New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX NO20043842L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35718102P 2002-02-15 2002-02-15
US42532502P 2002-11-12 2002-11-12
PCT/US2003/005384 WO2003070702A1 (en) 2002-02-15 2003-02-19 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix

Publications (1)

Publication Number Publication Date
NO20043842L true NO20043842L (en) 2004-09-14

Family

ID=27760457

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043842A NO20043842L (en) 2002-02-15 2004-09-14 New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX

Country Status (14)

Country Link
EP (1) EP1480950A4 (en)
JP (2) JP2005519076A (en)
KR (1) KR100724515B1 (en)
CN (1) CN100406436C (en)
AU (1) AU2003217653A1 (en)
CA (1) CA2475864A1 (en)
DE (1) DE03713610T1 (en)
ES (1) ES2241507T1 (en)
HR (1) HRP20040768A2 (en)
IS (1) IS7402A (en)
MX (1) MXPA04007939A (en)
NO (1) NO20043842L (en)
PL (1) PL372303A1 (en)
WO (1) WO2003070702A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2475123A1 (en) 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
EP1771412A2 (en) 2004-07-20 2007-04-11 Warner-Lambert Company LLC Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
CA2575243A1 (en) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
WO2006106372A1 (en) * 2005-04-08 2006-10-12 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság New crystalline atorvastatin hemicalcium salt polymorph form
US8084488B2 (en) 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
TW200745026A (en) * 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
EP2132171A4 (en) 2007-03-02 2010-11-17 Dong A Pharm Co Ltd Novel crystal forms of pyrrolylheptanoic acid derivatives
KR20120011249A (en) * 2010-07-28 2012-02-07 주식회사 경보제약 Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same
KR101324862B1 (en) * 2011-07-12 2013-11-01 (주)에이에스텍 Spherical particle of clopidogrel bisulfate, pharmaceutical composition comprising the same and method of preparation thereof
CR20200220A (en) 2013-11-15 2020-11-18 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN105055357A (en) * 2015-09-25 2015-11-18 青岛华之草医药科技有限公司 Atorvastatin calcium composition tablet for treating hypercholesteremia
KR101723783B1 (en) * 2017-02-24 2017-04-07 주식회사 경보제약 Novel Crystal Form of Atorvastatin Hemi-Calcium, Hydrate thereof, and Method of Producing the Same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI0848705T1 (en) * 1995-07-17 2002-04-30 Warner-Lambert Company Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
ES2349364T3 (en) * 1999-11-17 2010-12-30 Teva Pharmaceutical Industries, Ltd. PROCEDURE FOR THE PREPARATION OF A POLYMORPHIC FORM OF ATORVASTATIN CÁLCICA.
ES2252088T3 (en) * 1999-12-17 2006-05-16 Pfizer Science And Technology Ireland Limited PROCEDURE OF INDUSTRIAL SCALE PRODUCTION OF THE CALCIUM HEMISAL OF ATORVASTATIN CRYSTAL HYDROCHLATE.
AU780247B2 (en) * 1999-12-17 2005-03-10 Pfizer Science And Technology Ireland Limited A process for producing crystalline atorvastatin calcium
EP1332130A4 (en) * 2000-11-03 2004-01-21 Teva Pharma Atorvastatin hemi-calcium form vii
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
HUP0302519A3 (en) * 2000-12-27 2008-10-28 Teva Pharma Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
UA74075C2 (en) * 2001-06-29 2005-10-17 Warner Lambert Co NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS)
JP2005500351A (en) * 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド Atorvastatin calcium in crystalline form VI and VII
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
EP1572643A2 (en) * 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt

Also Published As

Publication number Publication date
WO2003070702A1 (en) 2003-08-28
JP2009235083A (en) 2009-10-15
PL372303A1 (en) 2005-07-11
EP1480950A4 (en) 2005-05-18
KR100724515B1 (en) 2007-06-04
ES2241507T1 (en) 2005-11-01
KR20040081202A (en) 2004-09-20
MXPA04007939A (en) 2004-11-26
HRP20040768A2 (en) 2005-06-30
EP1480950A1 (en) 2004-12-01
DE03713610T1 (en) 2005-10-20
CA2475864A1 (en) 2003-08-28
CN1646490A (en) 2005-07-27
JP2005519076A (en) 2005-06-30
CN100406436C (en) 2008-07-30
AU2003217653A1 (en) 2003-09-09
IS7402A (en) 2004-08-13

Similar Documents

Publication Publication Date Title
NO20043842L (en) New crystal forms of atorvastatin hemicalcium and processes for their preparation, as well as new processes for the preparation of atorvastatin hemicalcium forms I, VIII and IX
NO20032425D0 (en) New crystal forms of atorvastatin hemi-calcium and methods for their preparation, as well as new methods for the preparation of other forms
NO20035193D0 (en) New pyrrole derivatives as pharmaceuticals
ATE486597T1 (en) 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION
NO20034187L (en) Novel spirotric cyclic derivatives and their use as phosphodiesterase-7 inhibitors
CY2015015I1 (en) PRODUCTION OF THIACOMYCIN
DK1701946T3 (en) 1-piperazine and 1-homopiperazine carboxylate derivatives, their preparation and their therapeutic use as inhibitors of the FAAH enzyme
NO20043726L (en) Heteroaryl compounds useful as inhibitors of GSK-3
IS7768A (en) Methods for the production, isolation and purification of epothilone B, and the X-ray crystal structures of epothilone B
NO20061396L (en) New heterocyclic compounds as HSP90 inhibitors
NO20040933L (en) Novel gamma-secretase inhibitors.
NO20054876D0 (en) Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as drug and drug containing such compounds
ATE412649T1 (en) SUBSTITUTED HETEROARYLBENZOFURANIC ACIDS
NO20045554L (en) Procedure for the treatment of diabetes
NO20052859D0 (en) Process for the preparation of resperidone and its intermediates
NO20040996L (en) New Compounds and Compositions as Catepsin Inhibitors
NO20055657D0 (en) Novel bioisosters of actinonin
NO20070550L (en) Process for Preparation of Pyrrolotriazine Compounds
NO20044814L (en) Process for the preparation of combretastanines
DE602004023786D1 (en) Production of high purity alkylgallium
NO20050885L (en) New Process for the Synthesis of 1,3-Dihydro-2H-3-Benzazepin-2-One Compounds
NO331195B1 (en) Process for the preparation of halogen-substituted monosulfides and their hydroxymonosulfide equivalents as intermediates.
EA200501900A1 (en) NEW METHOD OF SYNTHESIS PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
NO20053910D0 (en) New piperazine derivatives and their use as synthesis intermediates.
EA200501925A1 (en) NEW METHOD OF SYNTHESIS PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application